Minoryx Therapeutics and Sperogenix Therapeutics enter into an exclusive license agreement to develop and commercialize leriglitazone in mainland China, Hong Kong and Macau

Minoryx Therapeutics and Sperogenix Therapeutics…

Immunic, Inc. Announces Dosing of First Healthy Volunteer in Phase 1 Clinical Program of IMU-856, Targeting Restoration of Intestinal Barrier Function

Immunic, Inc. Announces Dosing of…

Immunic, Inc. Announces Closing of $103.5 Million Public Offering, including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Immunic, Inc. Announces Closing of…

Immunic, Inc. Announces Pricing of $90.0 Million Public Offering of Common Stock

Immunic, Inc. Announces Pricing of…

Fund+ Establishes ExeVir Bio with VIB and UCB to Accelerate Development of New Treatment Conferring Broad Protection Against Covid-19

Fund+ Establishes ExeVir Bio with…

Fund+ Leads EUR38 Million Series B Financing in Indigo Diabetes NV

Fund+ Leads EUR38 Million Series…

Aelin Therapeutics awarded €2.3 million VLAIO research grant

Aelin Therapeutics awarded €2.3 million…

eTheRNA raises EUR 34 million in Series B financing to accelerate multiple mRNA therapeutic development programs through toclinical proof of concept

eTheRNA raises EUR 34 million…

Fund+ Announces Investment in Ona Therapeutics EUR30 Million Series A financing

Fund+ Announces Investment in Ona…

Immunic, Inc. Announces First Patients Dosed in its Phase 2, CALVID-1 Clinical Trial of IMU-838 in COVID-19

Immunic, Inc. Announces First Patients…